Home > Boards > US OTC > Biotechs > Caladrius Biosciences, Inc. (CLBS)

Four funds have new positions as of 2/12/21: https://whalewisdom.com/stock/nbs-2

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
slow_feet Member Profile
Member Level 
Followed By 28
Posts 2,801
Boards Moderated 2
Alias Born 09/13/00
160x600 placeholder
Caladrius Biosciences to Present at Zooming with LD GlobeNewswire Inc. - 7/22/2021 8:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 6/30/2021 4:08:36 PM
Caladrius Bio to assess CLBS201 in diabetic kidney disease Seeking Alpha - 6/22/2021 8:45:03 AM
Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease GlobeNewswire Inc. - 6/22/2021 8:00:00 AM
Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summi... GlobeNewswire Inc. - 6/17/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/16/2021 4:21:40 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/4/2021 4:46:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2021 4:46:02 PM
Caladrius Biosciences Announces Participation in Upcoming Conferences in June 2021 GlobeNewswire Inc. - 6/1/2021 8:30:00 AM
Caladrius shares rise on $1.4M non-dilutive funding Seeking Alpha - 5/12/2021 8:21:44 AM
Caladrius Biosciences Receives $1.4 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Tr... GlobeNewswire Inc. - 5/12/2021 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/6/2021 4:10:48 PM
Caladrius Biosciences EPS misses by $0.10 Seeking Alpha - 5/6/2021 4:10:30 PM
Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) Edgar (US Regulatory) - 5/6/2021 4:08:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2021 4:08:41 PM
Caladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 5/6/2021 4:05:00 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/5/2021 6:04:56 AM
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021 GlobeNewswire Inc. - 5/4/2021 9:00:00 AM
Caladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. East... GlobeNewswire Inc. - 4/29/2021 8:30:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/28/2021 4:05:09 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/28/2021 4:05:04 PM
Caladrius Biosciences files for $150M mixed shelf offering. Seeking Alpha - 4/1/2021 5:28:30 PM
Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease GlobeNewswire Inc. - 3/8/2021 8:00:00 AM
Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference GlobeNewswire Inc. - 3/3/2021 8:30:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 2/25/2021 4:10:55 PM
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences